Skip to content

Endoangel Withdrawal Overspeed Analysis

Explore the Relationship Between the Percentage of Overspeed of Colonoscopy Withdrawal and the Rate of Adenoma Detection:a Prospective、Multicenter、Observational Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05069571
Enrollment
1210
Registered
2021-10-06
Start date
2020-03-01
Completion date
2022-02-01
Last updated
2021-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Neoplasms

Brief summary

Exploring the relationship between the percentage of overspeed of colonoscopy withdrawal and the rate of adenoma detection.

Interventions

Collecting the colonoscopy videos and analyzing the correlation between withdrawal overspeed proportion and adenoma detection rate.

Sponsors

Renmin Hospital of Wuhan University
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Males or females who are over 18 years old (inclusive); 2. Enteroscopy and related examinations are needed to further clarify the characteristics of digestive tract diseases; 3. Able to read, understand and sign the informed consent form; 4. The researcher believes that the subject can understand the process of the clinical research, is willing and able to complete all the research procedures and follow-up visits, and cooperate with the research procedures.

Exclusion criteria

1. Participated in other clinical trials, signed an informed consent form and within the follow-up period of other clinical trials; 2. Abuse of drugs or alcohol or mental disorders in the last 5 years; 3. Women during pregnancy or breastfeeding; 4. Subjects with previous history of bowel surgery; 5. The investigator believes that the subject is not suitable for enteroscopy and related examinations; 6. The investigator believes that the subject is not suitable for high-risk diseases or other special circumstances to participate in clinical trials. 7. Patients with gastrointestinal bleeding; 8. Known or highly suspected allergy to any ingredient of bowel cleansing agent; 9. Restricted activities or any mental or physical condition impairs their ability to drink intestinal cleansing preparations; 10. Known or suspected intestinal obstruction or perforation, toxic megacolon, most colectomy, heart failure (grade III or IV), severe cardiovascular disease, severe liver failure or end, renal insufficiency, etc.

Design outcomes

Primary

MeasureTime frame
Adenoma detection rate3 months

Secondary

MeasureTime frame
Proportion of withdrawal overspeed3 months

Countries

China

Contacts

Primary ContactHonggang Yu, Doctor
yuhonggang@whu.edu.cn13871281899
Backup ContactLiwen Yao, Doctor
292779656@qq.com15827416837

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026